<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7122614/results/search/disease/results.xml">
  <result pre=": courier ; font-style : italic;} 978-3-319-47266-910.1007/978-3-319-47266-9Antimicrobial Drug ResistanceAntimicrobial Drug" exact="Resistance" post="Clinical and Epidemiological Aspects, Volume 2 978-3-319-47264-5978-3-319-47266-9 pmcid: 712261423"/>
  <result pre="Volume 2 978-3-319-47264-5978-3-319-47266-9 pmcid: 712261423 doi: 10.1007/978-3-319-47266-9_23 : Article Antiviral" exact="Resistance" post="in Influenza Viruses: Clinical and Epidemiological Aspects MayersDouglas L.+11617-995-9806dlmayers007@gmail.com1SobelJack"/>
  <result pre="de recherche en Infectiologie, University of Laval, [4], 0000000086837370grid.214458.eDivision of" exact="Infectious" post="Diseases, University of Michigan Medical School, [5], 0000 0004"/>
  <result pre="[5], 0000 0004 1937 0546grid.12136.37Infection Control and Prevention Unit of" exact="Infectious" post="Diseases, Assaf Harofeh Medical Center, Sackler Faculty of Medicine,"/>
  <result pre="VriesErhardPh.D.6IsonMichael G.M.D., M.S.mgison@northwestern.edu7[6], 0000 0001 0126 6191grid.412970.9Research Center for Emerging" exact="Infections" post="and Zoonoses, University of Veterinary Medicine, [7], 0000 0001"/>
  <result pre="University of Veterinary Medicine, [7], 0000 0001 2299 3507grid.16753.36Divisions of" exact="Infectious" post="Diseases and Organ Transplantation, Northwestern University Feinberg School of"/>
  <result pre="of Veterinary Medicine, [7], 0000 0001 2299 3507grid.16753.36Divisions of Infectious" exact="Diseases" post="and Organ Transplantation, Northwestern University Feinberg School of Medicine,"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="failure has been demonstrated in patients infected with viruses with" exact="primary" post="resistance, i.e., antivirals can be present in the virus"/>
  <result pre="nine NA subtypes recognized in nature [6], including highly pathogenic" exact="avian influenza" post="A/H5N1 and recent low-pathogenic avian influenza A/H7N9 viruses [7]."/>
  <result pre="[6], including highly pathogenic avian influenza A/H5N1 and recent low-pathogenic" exact="avian influenza" post="A/H7N9 viruses [7]. Since seasonal influenza is usually an"/>
  <result pre="seasonal influenza is usually an acute, self-limited illness in which" exact="viral" post="clearance usually occurs rapidly due to innate and adaptive"/>
  <result pre="the emergence of drug-resistant variants would be anticipated to have" exact="limited" post="effect on clinical recovery in otherwise healthy patients, as"/>
  <result pre="failure has been demonstrated in patients infected with viruses with" exact="primary" post="resistance, i.e., antivirals can be present in the virus"/>
  <result pre="nine NA subtypes recognized in nature [6], including highly pathogenic" exact="avian influenza" post="A/H5N1 and recent low-pathogenic avian influenza A/H7N9 viruses [7]."/>
  <result pre="[6], including highly pathogenic avian influenza A/H5N1 and recent low-pathogenic" exact="avian influenza" post="A/H7N9 viruses [7]. Since seasonal influenza is usually an"/>
  <result pre="seasonal influenza is usually an acute, self-limited illness in which" exact="viral" post="clearance usually occurs rapidly due to innate and adaptive"/>
  <result pre="the emergence of drug-resistant variants would be anticipated to have" exact="limited" post="effect on clinical recovery in otherwise healthy patients, as"/>
  <result pre="of resistant variants to compete with wild-type virus in the" exact="absence of" post="selective drug pressure, and the effects of resistance mutations"/>
  <result pre="selective drug pressure, and the effects of resistance mutations on" exact="viral" post="replication competence, pathogenicity, and transmissibility in vivo. Prior to"/>
  <result pre="mutation and were therefore highly resistant to oseltamivir while retaining" exact="susceptibility to" post="zanamivir. All currently circulating A/H1N1 and A/H3N2 viruses have"/>
  <result pre="date indicating that M2 inhibitor resistance is associated with worsened" exact="viral" post="virulence, atypical influenza, or enhanced transmissibility. Sporadic viruses with"/>
  <result pre="that M2 inhibitor resistance is associated with worsened viral virulence," exact="atypical" post="influenza, or enhanced transmissibility. Sporadic viruses with primary resistance"/>
  <result pre="associated with worsened viral virulence, atypical influenza, or enhanced transmissibility." exact="Sporadic" post="viruses with primary resistance mutations resulting in neuraminidase inhibitor"/>
  <result pre="viral virulence, atypical influenza, or enhanced transmissibility. Sporadic viruses with" exact="primary" post="resistance mutations resulting in neuraminidase inhibitor resistance have been"/>
  <result pre="M2 gene result in cross-resistance to both amantadine and rimantadine." exact="Resistance" post="emergence during therapy with neuraminidase inhibitors generally remains rare"/>
  <result pre="longer duration of replication in the presence of antiviral therapy." exact="Resistance" post="to neuraminidase inhibitors results from mutations in the neuraminidase"/>
  <result pre="resistance vary with drug, virus, and neuraminidase type and subtype." exact="Resistance" post="has been demonstrated to develop during the course of"/>
  <result pre="many with novel mechanisms of action, are currently undergoing development." exact="Resistance" post="mutations have been identified for many of these agents"/>
  <result pre="experimental animal models of influenza is incorporated to supplement the" exact="limited" post="data derived from clinical studies. M2 Ion Channel Inhibitors"/>
  <result pre="M2 ion channel allows the influx of protons into the" exact="viral" post="particle which, in turn, facilitates uncoating [17]. M2 inhibitors"/>
  <result pre="preserved in the presence of the inhibitor [3, 20, 21]." exact="Resistance" post="mutations do not affect transmissibility or replication fitness as"/>
  <result pre="viruses; documented transmission from person-to-person has been well established [22]." exact="Resistance" post="affects both drugs in the class equally and appears"/>
  <result pre="globally is resistant to this class of drugs [29, 30]." exact="Resistance" post="has resulted from the S31N substitution of the M2"/>
  <result pre="while most (~80 %) of clade 2.1 A/H5N1 are resistant" exact="secondary" post="to S31N or V27A substitution [31, 32, 37]. Of"/>
  <result pre="the prevention or treatment of influenza currently [2]. Detection of" exact="Resistance" post="There are currently no rapid tests that can screen"/>
  <result pre="United States this is actively done by the Centers for" exact="Diseases" post="Control and Prevention (http://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm). Detection of M2 inhibitor resistance"/>
  <result pre="M2 inhibitor resistance has usually relied on virus isolation from" exact="respiratory" post="samples and susceptibility testing of virus in cell culture."/>
  <result pre="PCR restriction length polymorphism (RFLP) analysis of RNA extracted from" exact="respiratory" post="samples using commercially available endonucleases for discrimination of point"/>
  <result pre="licensure of the M2 inhibitors, there were low levels of" exact="primary" post="resistance in community isolates (see Table 71.1). This began"/>
  <result pre="increased use of over-the-counter amantadine after the emergence of severe" exact="acute" post="respiratory syndrome (SARS) [38]. During the 2004–2005 influenza season,"/>
  <result pre="use of over-the-counter amantadine after the emergence of severe acute" exact="respiratory" post="syndrome (SARS) [38]. During the 2004–2005 influenza season, approximately"/>
  <result pre="of over-the-counter amantadine after the emergence of severe acute respiratory" exact="syndrome" post="(SARS) [38]. During the 2004–2005 influenza season, approximately 70"/>
  <result pre="to M2 inhibitors (Table 71.1). This spread occurred despite the" exact="absence of" post="sustained selective drug pressure, possibly because the resistant M"/>
  <result pre="that this resistance mutation does not reduce transmissibility and is" exact="stable" post="over time. Table 71.1 Representative studies of M2 inhibitor"/>
  <result pre="to the Ser31Asn mutation [29, 30]. Fortunately, the incidence of" exact="primary" post="resistance declined in 2008 and 2009 among seasonal A/H1N1"/>
  <result pre="to M2 inhibitors [46]. The postulated role of swine as" exact="intermediate" post="hosts in the emergence of some novel human viruses"/>
  <result pre="while most (~80 %) of clade 2.1 A/H5N1 are resistant" exact="secondary" post="to Ser31Asn or Val27Ala substitution [32, 37]. Of note,"/>
  <result pre="Ser31Asn mutation conferring resistance to the M2 inhibitors [49, 50]." exact="Resistance" post="in Posttreatment Isolates Studies in experimentally infected animals and"/>
  <result pre="the common emergence of resistant variants as the course of" exact="infection" post="progresses over time. Following treatment, approximately 70–90 % of"/>
  <result pre="commonly and rapidly in M2 inhibitor-treated children and adults with" exact="acute" post="influenza (Table 71.2). One study of adults found that"/>
  <result pre="day 3 of treatment, although the nasal lavage titers were" exact="lower" post="than in placebo recipients shedding susceptible virus [27]. Another"/>
  <result pre="virus [27]. Another study found that 33 % of 24" exact="adult" post="and pediatric household members receiving rimantadine shed resistant virus"/>
  <result pre="serve as a reservoir for nosocomial transmission. One study of" exact="adult" post="bone marrow transplant and acute leukemia patients recovered resistant"/>
  <result pre="nosocomial transmission. One study of adult bone marrow transplant and" exact="acute" post="leukemia patients recovered resistant virus in 5 (33 %)"/>
  <result pre="transmission. One study of adult bone marrow transplant and acute" exact="leukemia" post="patients recovered resistant virus in 5 (33 %) of"/>
  <result pre="transplanted SCID child who shed for 5 weeks and one" exact="adult" post="leukemia patient who shed resistant virus for ≥1 week"/>
  <result pre="SCID child who shed for 5 weeks and one adult" exact="leukemia" post="patient who shed resistant virus for ≥1 week of"/>
  <result pre="transmit through three more sets of contact birds in the" exact="absence of" post="selective drug pressure. Resistant virus was detected from the"/>
  <result pre="In contrast, two studies have found no significant reduction in" exact="secondary" post="influenza illness in household contacts receiving either amantadine or"/>
  <result pre="and one of these documented failures of prophylaxis due to" exact="infection" post="by drug-resistant variants, most likely transmitted from the treated"/>
  <result pre="Yes 11/400 (3 %) 40//392 (10 %) 73 aClinical influenza" exact="Chronic" post="Care Facilities Transmission of M2 inhibitor-resistant viruses is well"/>
  <result pre="to 76 % [59]. Studies have demonstrated patients who developed" exact="infections" post="with resistant viruses, typically with the Ser31Asn mutation, in"/>
  <result pre="symptoms [25, 27]. Illness occurs in both the presence and" exact="absence of" post="the drug, a finding that indicates the loss of"/>
  <result pre="loss of antiviral effectiveness in vivo. Although severe and progressive" exact="infection" post="with resistant virus has been noted in immunocompromised and"/>
  <result pre="noted for some avian A/H7 viruses, this reversion in the" exact="absence of" post="selective drug pressure suggests diminished replication competence of some"/>
  <result pre="had no impact of virulence, mortality, febrile responses, peak nasal" exact="viral" post="titers, or nasal inflammatory cell counts [22, 51]. In"/>
  <result pre="wild-type viruses, and resistance phenotypes were typically retained in the" exact="absence of" post="drug. In treated patients the emergence of resistant virus"/>
  <result pre="emergence of resistant virus may be associated with persistence of" exact="viral" post="recovery and in some studies delays in resolution of"/>
  <result pre="placebo-treated patients [23, 27]. Patients may have worsening symptoms or" exact="viral" post="titers when resistance emerges as well [23]. Treatment Alternatives"/>
  <result pre="vivo, and in infected patient and appears effective at inhibiting" exact="viral" post="replication in vitro and improved outcomes in vivo [65,"/>
  <result pre="receptor-binding and NA receptor-destroying properties [78]. Mechanisms which influence the" exact="viral" post="HA/NA functional balance may have played a role in"/>
  <result pre="beginning of 2007–2008 influenza season [97–99]. Detection of NA Inhibitor" exact="Resistance" post="Unlike the situation for M2 inhibitors, cell culture-based assays"/>
  <result pre="because of the differences in cellular receptor specificity between human" exact="respiratory" post="epithelium and available cell culture types (reviewed in [71])."/>
  <result pre="date [100, 101]. Other challenges are the broad variation in" exact="morphology" post="of influenza plaques between different influenza types and subtypes"/>
  <result pre="against variants with either the His274Tyr or Glu119Val mutation and" exact="partial" post="activity against the Arg292Lys variant [114]. Viruses with a"/>
  <result pre="71.4 Effects of NA mutations that confer oseltamivir resistance on" exact="viral" post="fitness measures in clinical isolates of influenza Virus (ref)"/>
  <result pre="day, respectively; P &amp;gt; .05). HA binding efficiency and associated" exact="susceptibility to" post="NA inhibitors are affected by amino acid changes in"/>
  <result pre="in vitro to all NA inhibitors but in general retain" exact="susceptibility to" post="NA inhibitors in vitro and in animal models [118–120]."/>
  <result pre="= 1799), no genotypic resistance was detected at baseline in" exact="respiratory" post="specimens of influenza A or B virus-infected patients apart"/>
  <result pre="change was detected. In two oseltamivir-treated children with an A/H3N2" exact="virus infection," post="an Arg292Lys change emerged posttreatment. Although the incidence of"/>
  <result pre="viruses with an His274Tyr are a reason for concern [122–124]." exact="Resistance" post="to zanamivir was reported due to an amino change"/>
  <result pre="(MDCK) cell cultures [127]. With regard to the highly pathogenic" exact="avian influenza" post="A/H5N1 viruses and low-pathogenic avian influenza A/H7N9 viruses, these"/>
  <result pre="to the highly pathogenic avian influenza A/H5N1 viruses and low-pathogenic" exact="avian influenza" post="A/H7N9 viruses, these are susceptible to the NA inhibitors"/>
  <result pre="been the major antiviral resistance pattern found in highly pathogenic" exact="avian influenza" post="A/H5N1 viruses [130–133], a A/H5N1 isolate was reported [130],"/>
  <result pre="emergence of an Arg292Lys amino acid change in the low-pathogenic" exact="avian influenza" post="A/H7N9 viruses circulating in China since 2013 causes high"/>
  <result pre="PCR polymerase chain reaction aOne B/Perth/211/2001 isolate had ninefold reduced" exact="susceptibility to" post="zanamivir and 14-fold to oseltamivir compared to the mean"/>
  <result pre="a Asp197Glu mutation [79] bFour isolates (0.5 %) with NA" exact="deficiency" post="were found to be resistant to NA inhibitors in"/>
  <result pre="contrasted with unit dosing in most countries, is associated with" exact="lower" post="drug exposure in young children. This has been postulated"/>
  <result pre="detected in two subjects in association with apparent rebounds in" exact="viral" post="replication [148]. This study found that oseltamivir-treated subjects were"/>
  <result pre="oseltamivir-treated subjects were less likely than placebo to have late" exact="viral" post="isolates showing reversion of the egg-adapted inoculum virus to"/>
  <result pre="treated with oseltamivir and zanamivir with mutations in both the" exact="viral" post="HA and NA glycoproteins [8, 10, 12, 161]. Most"/>
  <result pre="clearly needed for these patients. Pathogenicity and Transmissibility of Resistant" exact="Variant" post="Before the 2007–2008 influenza season, it was thought that"/>
  <result pre="the Arg152Lys mutation in influenza B NA that confers reduced" exact="susceptibility to" post="zanamivir [178]. Given these findings, most experts recommend using"/>
  <result pre="oseltamivir-resistant infections; success is less likely in patients with influenza" exact="pneumonia" post="[179–182]. Intravenous zanamivir has been utilized most frequently for"/>
  <result pre="there are no reports of its use in human influenza" exact="infections" post="due to such variants. Ribavirin combined with a NA"/>
  <result pre="more effective than ribavirin alone against a lethal influenza A(H1N1)" exact="infection" post="but superior to single agents against influenza B [189]."/>
  <result pre="studied in vitro, in vivo, and in humans with influenza" exact="infection" post="[65, 66, 190]. Given the promise of this combination,"/>
  <result pre="and influenza B; the 2009 pandemic A/H1N1 virus; highly pathogenic" exact="avian influenza" post="virus A/H5N1 isolated from humans; A/H1N1 and A/H1N2 isolated"/>
  <result pre="A/H1N1 viruses in MDCK cell lines in the presence or" exact="absence of" post="low concentrations of favipiravir, no favipiravir-resistant viruses were phenotypically"/>
  <result pre="arise at the antibody target sites, which may result in" exact="viral" post="escape. Implications and Future Research Directions Currently, circulating strains"/>
  <result pre="but are generally susceptible to the clinically available neuraminidase inhibitors." exact="Sporadic" post="cases of neuraminidase inhibitor resistance have been recognized, and"/>
  <result pre="Sporadic cases of neuraminidase inhibitor resistance have been recognized, and" exact="limited" post="regional transmission has been demonstrated [4, 44, 198]. Further,"/>
  <result pre="has been demonstrated to emerge during therapy in highly pathogenic" exact="avian influenza" post="viruses that infect humans, with the highest frequency in"/>
  <result pre="49]. As such, most regions of the world are currently" exact="limited" post="to a single class of drug, the neuraminidase inhibitor,"/>
  <result pre="of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other" exact="avian influenza" post="virusesAntimicrob Agents Chemother2001451027233210.1128/AAC.45.10.2723-2732.200111557461 7.ItohYet al.Emergence of H7N9 influenza A"/>
  <result pre="treated with oseltamivir: descriptive studyLancet200436494367596510.1016/S0140-6736(04)16934-115337401 9.van der VriesEet al.Outcomes and" exact="susceptibility to" post="neuraminidase inhibitors in individuals infected with different influenza B"/>
  <result pre="the influenza resistance information studyJ Infect Dis201621321839010.1093/infdis/jiv37526160744 10.GooskensJet al.Prolonged influenza" exact="virus infection" post="during lymphocytopenia and frequent detection of drug-resistant virusesJ Infect"/>
  <result pre="influenza resistance information studyJ Infect Dis201621321839010.1093/infdis/jiv37526160744 10.GooskensJet al.Prolonged influenza virus" exact="infection" post="during lymphocytopenia and frequent detection of drug-resistant virusesJ Infect"/>
  <result pre="al.Common emergence of amantadine- and rimantadine-resistant influenza A viruses in" exact="symptomatic" post="immunocompromised adultsClin Infect Dis199826614182410.1086/5163589636873 29.BrightRAet al.Adamantane resistance among influenza"/>
  <result pre="A(H3N2) and A(H1N1) viruses isolated worldwideJ Infect Dis200719622495710.1086/51893617570112 31.Novel Swine-Origin" exact="Influenza A (H1N1)" post="Virus Investigation Team. Emergence of a novel swine-origin influenza"/>
  <result pre="of the World Health Organization Consultation on Human Influenza, A.H." exact="Avian" post="influenza A (H5N1) infection in humans. N Engl J"/>
  <result pre="Organization Consultation on Human Influenza, A.H. Avian influenza A (H5N1)" exact="infection" post="in humans. N Engl J Med. 2005;353(13):1374–85. 33.GovorkovaEAet al.Antiviral"/>
  <result pre="for continued monitoringAntiviral Res201398229730410.1016/j.antiviral.2013.02.01323458714 34.StonerTDet al.Antiviral susceptibility of avian and" exact="swine influenza" post="virus of the N1 neuraminidase subtypeJ Virol201084199800910.1128/JVI.00296-1020660186 35.MarjukiHet al.Neuraminidase"/>
  <result pre="Res2007732112710.1016/j.antiviral.2006.08.00216963130 44.OhDYHurtACA review of the antiviral susceptibility of human and" exact="avian influenza" post="viruses over the last decadeScientifica (Cairo)2014201443062924800107 45.ItoTet al.Evolutionary analysis"/>
  <result pre="influenza A (H7N9) virus infectionN Engl J Med20133682422778510.1056/NEJMoa130558423697469 50.GaoRet al.Human" exact="infection" post="with a novel avian-origin influenza A (H7N9) virusN Engl"/>
  <result pre="of influenza viruses to neuraminidase inhibitors—a reviewAntiviral Res200047111710.1016/S0166-3542(00)00103-010930642 71.TisdaleMMonitoring of" exact="viral" post="susceptibility: new challenges with the development of influenza NA"/>
  <result pre="neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza virusesPLoS Pathog2014104e100406510.1371/journal.ppat.100406524699865 80.BloomJDGongLIBaltimoreDPermissive" exact="secondary" post="mutations enable the evolution of influenza oseltamivir resistanceScience201032859831272510.1126/science.118781620522774 81.LiYet"/>
  <result pre="91.DharanNJet al.Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal" exact="Influenza A (H1N1)" post="infection during the 2007–2008 influenza season in the United"/>
  <result pre="of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal Influenza A (H1N1)" exact="infection" post="during the 2007–2008 influenza season in the United StatesClin"/>
  <result pre="al.Global assessment of resistance to neuraminidase inhibitors, 2008–2011: the Influenza" exact="Resistance" post="Information Study (IRIS)Clin Infect Dis2013569119720510.1093/cid/cis122023307766 104.HurtACOkomo-AdhiamboMGubarevaLVThe fluorescence neuraminidase inhibition"/>
  <result pre="Influenza A(H3N2) virusesAntimicrob Agents Chemother20155942374910.1128/AAC.04939-1425645846 111.RussellRJet al.The structure of H5N1" exact="avian influenza" post="neuraminidase suggests new opportunities for drug designNature2006443710745910.1038/nature0511416915235 112.GubarevaLVMolecular mechanisms"/>
  <result pre="pandemic influenza A (H1N1) virusN Engl J Med2010363141381210.1056/NEJMc100374920879894 118.McKimm-BreschkinJLet al.Reduced" exact="susceptibility to" post="all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin"/>
  <result pre="119.AbedYet al.Characterization of 2 influenza A(H3N2) clinical isolates with reduced" exact="susceptibility to" post="neuraminidase inhibitors due to mutations in the hemagglutinin geneJ"/>
  <result pre="severe influenzaLancet Infect Dis2014141212597010.1016/S1473-3099(14)70821-725213733 129.HurtACet al.Susceptibility of highly pathogenic A(H5N1)" exact="avian influenza" post="viruses to the neuraminidase inhibitors and adamantanesAntiviral Res20077332283110.1016/j.antiviral.2006.10.00417112602 130.LeQMet"/>
  <result pre="isolation of drug-resistant H5N1 virusNature20054377062110810.1038/4371108a16228009 131.BeigelJHet al.Avian influenza A (H5N1)" exact="infection" post="in humansN Engl J Med20053531313748510.1056/NEJMra05221116192482 132.de JongMDet al.Oseltamivir resistance"/>
  <result pre="(H5N1) infectionN Engl J Med20053532526677210.1056/NEJMoa05451216371632 133.de JongMDet al.Brief report: Fatal" exact="avian influenza" post="A (H5N1) in a child presenting with diarrhea followed"/>
  <result pre="Fatal avian influenza A (H5N1) in a child presenting with" exact="diarrhea" post="followed by comaN Engl J Med200535276869110.1056/NEJMoa04430715716562 134.KisoMet al.Effect of"/>
  <result pre="virus H7N9 isolate can be masked by a mixed R/K" exact="viral" post="populationMBio.201344e00396e0031310.1128/mBio.00396-1323860768 139.HuYet al.Association between adverse clinical outcome in human"/>
  <result pre="viral populationMBio.201344e00396e0031310.1128/mBio.00396-1323860768 139.HuYet al.Association between adverse clinical outcome in human" exact="disease" post="caused by novel influenza A H7N9 virus and sustained"/>
  <result pre="disease caused by novel influenza A H7N9 virus and sustained" exact="viral" post="shedding and emergence of antiviral resistanceLancet201338198852273910.1016/S0140-6736(13)61125-323726392 140.HaiRet al.Influenza A(H7N9)"/>
  <result pre="al.Global assessment of resistance to neuraminidase inhibitors: 2008–2011. The Influenza" exact="Resistance" post="Information Study (IRIS)Clin Infect Dis201356119720510.1093/cid/cis122023307766 142.HurtACet al.Neuraminidase inhibitor-resistant and"/>
  <result pre="treated with oseltamivirJ Infect Dis200118345233110.1086/31853711170976 149.BeheraAKBasuSCherianSSMolecular mechanism of the enhanced" exact="viral" post="fitness contributed by secondary mutations in the hemagglutinin protein"/>
  <result pre="Dis200118345233110.1086/31853711170976 149.BeheraAKBasuSCherianSSMolecular mechanism of the enhanced viral fitness contributed by" exact="secondary" post="mutations in the hemagglutinin protein of oseltamivir resistant H1N1"/>
  <result pre="outcomes in hematopoietic cell transplant patients infected with influenza virusBiol" exact="Blood" post="Marrow Transplant20111779798610.1016/j.bbmt.2010.09.01420870025 153.IsonMGet al.End points for testing influenza antiviral"/>
  <result pre="severe and life-threatening diseaseJ Infect Dis20102011116546210.1086/65249820423224 154.KhannaNet al.Outcome of influenza" exact="infections" post="in outpatients after allogeneic hematopoietic stem cell transplantationTranspl Infect"/>
  <result pre="et al. Clinical aspects of pandemic 2009 influenza A (H1N1)" exact="virus infection." post="N Engl J Med. 2010;362(18):1708–19. 156.IsonMGInfluenza prevention and treatment"/>
  <result pre="adults with cancerPediatr Infect Dis J2011304284810.1097/INF.0b013e3181ff863b21048522 158.FraaijPLet al.Viral shedding and" exact="susceptibility to" post="oseltamivir in hospitalized immunocompromised patients with influenza in the"/>
  <result pre="oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza" exact="Resistance" post="Information Study (IRIS)Antivir Ther20152066334210.3851/IMP295725849228 159.BazMet al.Emergence of oseltamivir-resistant pandemic"/>
  <result pre="with death or hospitalization due to pandemic 2009 influenza A(H1N1)" exact="infection" post="in CaliforniaJAMA200930217189690210.1001/jama.2009.158319887665 163.IvesJAet al.The H274Y mutation in the influenza"/>
  <result pre="model for evaluating the potential spread of drug-resistant influenza virus" exact="infections" post="during community-based use of antiviralsJ Antimicrob Chemother20035149779010.1093/jac/dkg13612654752 165.HerlocherMLet al.Influenza"/>
  <result pre="in ferretsAntiviral Res20025429911110.1016/S0166-3542(01)00214-512062395 166.DuanSet al.Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses" exact="lower" post="transmissibility and fitness in ferretsPLoS Pathog201067e100102210.1371/journal.ppat.100102220686654 167.HamelinMEet al.Oseltamivir-resistant pandemic"/>
  <result pre="179.ChenLFet al.Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus" exact="infections" post="on a hospital ward among immunocompromised patients—North Carolina, 2009J"/>
  <result pre="al.The use of zanamivir to treat influenza A and B" exact="infection" post="after allogeneic stem cell transplantationBone Marrow Transplant2002292113510.1038/sj.bmt.170334311850704 182.PetersenEet al.Failure"/>
  <result pre="features from patients infected with re-emergent avian-origin human H7N9 influenza" exact="disease" post="of varying severity in Guangdong provincePLoS One2015102e011784610.1371/journal.pone.011784625723593 187.HaydenFGNewer influenza"/>
  <result pre="Respir Viruses20137Suppl 1637510.1111/irv.1204523279899 188.SmeeDFet al.Combination treatment of influenza A virus" exact="infections" post="in cell culture and in mice with the cyclopentane"/>
  <result pre="of oseltamivir and ribavirin used alone and in combination against" exact="infections" post="in mice with recent isolates of influenza A (H1N1)"/>
  <result pre="infection: safety and pharmacokineticsAntivir Ther20131833778610.3851/IMP247523264438 191.FurutaYet al.Favipiravir (T-705), a novel" exact="viral" post="RNA polymerase inhibitorAntiviral Res201310024465410.1016/j.antiviral.2013.09.01524084488 192.SleemanKet al.In vitro antiviral activity"/>
  <result pre="therapeutically harness the human antibody responseNat Rev Immunol201212107091910.1038/nri328523007571 195.ImpagliazzoAet al.A" exact="stable" post="trimeric influenza hemagglutinin stem as a broadly protective immunogenScience201534962541301610.1126/science.aac726326303961"/>
  <result pre="criteriaInfluenza Other Respir Viruses2014822586510.1111/irv.1221524299049 199.NichollsJMMossRBHaslamSMThe use of sialidase therapy for" exact="respiratory" post="viral infectionsAntiviral Res2013983401910.1016/j.antiviral.2013.04.01223602850 200.HaffizullaJet al.Effect of nitazoxanide in adults"/>
  <result pre="Other Respir Viruses2014822586510.1111/irv.1221524299049 199.NichollsJMMossRBHaslamSMThe use of sialidase therapy for respiratory" exact="viral" post="infectionsAntiviral Res2013983401910.1016/j.antiviral.2013.04.01223602850 200.HaffizullaJet al.Effect of nitazoxanide in adults and"/>
  <result pre="Res2013983401910.1016/j.antiviral.2013.04.01223602850 200.HaffizullaJet al.Effect of nitazoxanide in adults and adolescents with" exact="acute" post="uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trialLancet"/>
  <result pre="Med20073563312310.1056/NEJMc06298917229966 208.GalbraithAWet al.Protective effect of 1-adamantanamine hydrochloride on influenza A2" exact="infections" post="in the family environment: a controlled double-blind studyLancet1969276291026810.1016/S0140-6736(69)90639-44187541 209.BricaireFet"/>
  <result pre="to different neuraminidase inhibitorsAntiviral Res2002543143710.1016/S0166-3542(01)00219-412062387 218.MungallBAXuXKlimovASurveillance of influenza isolates for" exact="susceptibility to" post="neuraminidase inhibitors during the 2000–2002 influenza seasonsVirus Res20041031-2195710.1016/j.virusres.2004.02.03315163509 219.FerrarisOKesslerNLinaBSensitivity"/>
  <result pre="Chemother200555Suppl 1i52110.1093/jac/dki01815709056 225.StephensonIet al.Neuraminidase inhibitor resistance after oseltamivir treatment of" exact="acute" post="influenza A and B in childrenClin Infect Dis20094843899610.1086/59631119133796 226.TramontanaARet"/>
  <result pre="and B in childrenClin Infect Dis20094843899610.1086/59631119133796 226.TramontanaARet al.Oseltamivir resistance in" exact="adult" post="oncology and hematology patients infected with pandemic (H1N1) 2009"/>
 </snippets>
</snippetsTree>
